Highly active multiple sclerosis: An update

被引:63
作者
Diaz, Cindy [1 ]
Alfonso Zarco, Luis [2 ]
Rivera, Diego M. [3 ]
机构
[1] Univ Javeriana, Hosp Univ San Ignacio, Dept Neurol, Bogota, Colombia
[2] Univ Javeriana, Hosp Univ San Ignacio, Neurol Serv, Bogota, Colombia
[3] Univ Pontifica Javeriana, Hosp Univ San Ignacio, Bogota, Colombia
关键词
Review; Multiple sclerosis; Highly active multiple sclerosis; STEM-CELL TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; LONG-TERM; FOLLOW-UP; CORTICAL DEMYELINATION; GLATIRAMER ACETATE; DISEASE-ACTIVITY; CONTROLLED-TRIAL; NATURAL-HISTORY; ORAL CLADRIBINE;
D O I
10.1016/j.msard.2019.01.039
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide. It is characterized by brain and spinal cord involvement. There are the relapsing remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS) phenotypes. There is a subgroup of RRMS patients who have a more aggressive disease course marked by a rapid accumulation of physical and cognitive deficit, despite treatment with 1 or more disease modifying drugs (DMTs). In the past, this disease phenotype was called "aggressive" MS (AMS); it is now called highly active MS (HAMS). It is generally agreed that the severe nature of this phenotype requires different treatment decisions. Unfortunately, there is no consensus on the definition of AMS or the treatment algorithm. In this article we review HAMS in relation to its definition and the treatments available.
引用
收藏
页码:215 / 224
页数:10
相关论文
共 84 条
[1]   Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions [J].
Absinta, Martina ;
Sati, Pascal ;
Schindler, Matthew ;
Leibovitch, Emily C. ;
Ohayon, Joan ;
Wu, Tianxia ;
Meani, Alessandro ;
Filippi, Massimo ;
Jacobson, Steven ;
Cortese, Irene C. M. ;
Reich, Daniel S. .
JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (07) :2597-2609
[2]   A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials [J].
Amato, MP ;
Ponziani, G ;
Bartolozzi, ML ;
Siracusa, G .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 168 (02) :96-106
[3]  
[Anonymous], 1989, PROGNOSTIC FACTORS M, P117
[4]   Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned [J].
Atkins, Harold L. ;
Freedman, Mark S. .
NEUROTHERAPEUTICS, 2013, 10 (01) :68-76
[5]  
Awad A., 2009, Ther. Adv. Neurol. Disord, V2, P357, DOI [10.1177/1756285609344375, DOI 10.1177/1756285609344375]
[6]   Treatment of multiple sclerosis with Anti-CD20 antibodies [J].
Barun, Barbara ;
Bar-Or, Amit .
CLINICAL IMMUNOLOGY, 2012, 142 (01) :31-37
[7]   Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis [J].
Bergamaschi, R ;
Berzuini, C ;
Romani, A ;
Cosi, V .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 189 (1-2) :13-21
[8]   Multiple sclerosis: long-term remission after a high dose of cyclophosphamide [J].
Bittencourt, PRM ;
Gomes-da-Silva, MM .
ACTA NEUROLOGICA SCANDINAVICA, 2005, 111 (03) :195-198
[9]   Subpial demyelination in the cerebral cortex of multiple sclerosis patients [J].
Bo, L ;
Vedeler, CA ;
Nyland, HI ;
Trapp, BD ;
Mork, SJ .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (07) :723-732
[10]  
Burt RK, 2009, LANCET NEUROL, V8, P244, DOI 10.1016/S1474-4422(09)70017-1